GW Pharmaceuticals tests epilepsy drug in man as FDA softens stance

A.B. | ShareCast | 18 Sep, 2013 11:09 - Updated: 11:59 | | |

Drugs
  • n/a
  • n/an/a
  • Max: n/a
  • Min: n/a
  • Volumen: n/a
  • MM 200 : n/a
n/a
  • n/a
  • n/an/a
  • Max: n/a
  • Min: n/a
  • Volumen: n/a
  • MM 200 : n/a
n/a
  • n/a
  • n/an/a
  • Max: n/a
  • Min: n/a
  • Volumen: n/a
  • MM 200 : n/a
n/a

Cannabis-derived drug developer GW Pharmaceuticals has begun human trials of its epilepsy treatment.

The AIM- and Nasdaq-listed company said the novel drug candidate, currently named GWP42006, was one of its most promising and looked to have significantly fewer side effects than currently approved anti-epileptic drugs.

Dr. Stephen Wright, Director of Research and Development at the company said advancing GWP42006 to a first dose in man was a significant milestone in the development of this candidate.

“The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," he added.

"We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Research with the Reading School of Pharmacy in Buckinghamshire has shown that GWP42006 not only exerts significant ability to treat seizures in a wide range of preclinical models of seizure and epilepsy, but is also better tolerated by patients compared to existing anti-epileptic drugs.

The company has been encouraged by recent interest in its products in the US. That arose after the pharmaceutical regulator, the Food and Drug Administration [FDA], allowed US epilepsy specialists and patient organizations to carry out treatment on a small number of pediatric epilepsy patients with a cannabidiol [CBD] formulation supplied by GW. These activities may generate initial evidence to add CBD as a further pipeline candidate for clinical evaluation in epilepsy.

Recent third quarter showed net cash of $66.3m thanks to a US IPO in May that raised $30.4m.

Shares in GWP were up 1.4% to 72p at 11:12 on Wednesday.

OH

More news

23 Jan US close: Markets mixed following ECB decision and lower than expected home sales

US stocks were mixed on Friday after the positive impact of the ECB failed to last into the afternoon.

23 Jan Friday tips round-up: Standard Life, Monitise

Shareholders in Standard Life are sitting pretty after the relevant authorities cleared the way for the firm to payout £1.75bn in cash. That comes in the wake of the £2.2bn sale of its Canadian arm last September. That will result in a large outflow of capital, which will nonetheless be compensated for by a share consolidation. Yet what really matters is the company’s constant solid performance.

23 Jan Week ahead: US Fed meeting in focus

Investors next week are expected to concentrate on the result of the Federal Reserve’s monetary policy meeting, on Wednesday.

23 Jan FTSE 250 movers: Jimmy Choo rallies after trading update

Jimmy Choo was topping the FTSE 250 after reporting net revenue rose 12% to £299m last year, driven by growth in Asia. In its first trading update since listing on the London Stock Exchange in October, the luxury shoe maker said it was “delighted” with sales which were helped by new store openings in China and a strong performance in Japan.

23 Jan Market overview: FTSE 100 finishes up 0.5%

1630: Close UK stocks finished at levels not seen in over four months, lifted by improving economic data and continued optimism surrounding a massive bond-buying plan by the ECB. The FTSE 100 settled up 0.5% at 6,832.83 by the end of the session despite heavy falls in the mining sector. This was the index's first close above the 6,800 mark since 19 September 2014. However, nervousness ahead of Sunday's general election in Greece was limiting gains. Analysts at Barclays said that while the latest polls suggest a victory for the anti-austerity Syriza party, "we nonetheless do not rule out a more adverse scenario in which a second round of general elections are needed, prolonging political uncertainty, affecting the economy".

23 Jan ECB's QE programme could be extended or expanded, says Coeure

European Central Bank (ECB) Executive Board member Benoit Coeure said the quantitative easing (QE) programme announced on Thursday could be extended or expanded if it fails to lift inflation.

23 Jan London close: Stocks at highest since September on ECB optimism, upbeat data

UK stocks pushed higher on Friday, finishing at levels not seen in over four months, lifted by improving economic data and continued optimism surrounding a massive bond-buying plan by the European Central Bank (ECB).

23 Jan Europe close: Stocks rally after ECB's Coeure says QE could be extended

Stocks in the euro-area gained after European Central Bank (ECB) Executive Board member Benoit Coeure said the quantitative easing (QE) programme could be extended or expanded if the impact on inflation was not enough.

23 Jan RM2 chairman raises stake

The children of RM2 International's chairman acquired some shares in the pallet manufacturer company as part of the Swiftsure Trust.

23 Jan Drax rises after EU approves state aid for MGT Power

The European Union has given the green light for the UK government to provide financial aid to MGT Power’s biomass power station in the North East of England.